Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Wedbush dropped their Q2 2026 earnings per share (EPS) estimates for Ardelyx in a note issued to investors on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.01. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx's FY2026 earnings at $0.07 EPS, FY2027 earnings at $0.42 EPS, FY2028 earnings at $0.70 EPS and FY2029 earnings at $0.96 EPS.
A number of other analysts also recently weighed in on ARDX. Wall Street Zen downgraded shares of Ardelyx from a "hold" rating to a "sell" rating in a report on Monday, May 5th. Raymond James Financial downgraded Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 target price on the stock. in a research report on Friday, May 2nd. HC Wainwright assumed coverage on Ardelyx in a research note on Wednesday, June 18th. They set a "buy" rating and a $10.00 price target on the stock. Finally, Citigroup reduced their price objective on Ardelyx from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $10.89.
Check Out Our Latest Stock Analysis on ARDX
Ardelyx Stock Performance
ARDX traded down $0.07 during midday trading on Wednesday, reaching $4.54. The company's stock had a trading volume of 1,808,066 shares, compared to its average volume of 4,429,096. The company has a fifty day simple moving average of $3.90 and a 200 day simple moving average of $4.72. The stock has a market cap of $1.09 billion, a P/E ratio of -20.66 and a beta of 0.60. The company has a current ratio of 4.12, a quick ratio of 3.81 and a debt-to-equity ratio of 1.04. Ardelyx has a twelve month low of $3.21 and a twelve month high of $7.18.
Ardelyx (NASDAQ:ARDX - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Ardelyx had a negative return on equity of 34.45% and a negative net margin of 14.86%. The firm had revenue of $74.11 million during the quarter, compared to the consensus estimate of $79.40 million. During the same quarter last year, the business earned ($0.11) EPS. The business's revenue was up 61.1% compared to the same quarter last year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of ARDX. GF Fund Management CO. LTD. acquired a new position in shares of Ardelyx during the fourth quarter worth approximately $25,000. Cyndeo Wealth Partners LLC bought a new stake in Ardelyx during the 1st quarter worth about $49,000. Quarry LP acquired a new position in Ardelyx during the 4th quarter valued at about $51,000. Rehmann Capital Advisory Group bought a new position in shares of Ardelyx in the 4th quarter valued at about $51,000. Finally, Focus Partners Advisor Solutions LLC acquired a new stake in shares of Ardelyx during the 1st quarter worth approximately $56,000. Institutional investors own 58.92% of the company's stock.
Insider Buying and Selling at Ardelyx
In related news, CEO Michael Raab sold 46,817 shares of Ardelyx stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total transaction of $191,013.36. Following the completion of the transaction, the chief executive officer directly owned 1,547,937 shares of the company's stock, valued at $6,315,582.96. This trade represents a 2.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Justin A. Renz sold 7,218 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total transaction of $29,449.44. Following the completion of the transaction, the chief financial officer owned 416,089 shares in the company, valued at approximately $1,697,643.12. This trade represents a 1.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 881,377 shares of company stock worth $3,402,411 and have sold 125,143 shares worth $517,667. Corporate insiders own 4.80% of the company's stock.
About Ardelyx
(
Get Free Report)
Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
See Also
Before you consider Ardelyx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.
While Ardelyx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
